Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5725086 | Respiratory Medicine Case Reports | 2017 | 5 Pages |
Abstract
In the past decade novel agents are on the market for non-small cell lung cancer adenocarcinoma based on pharmacogenomics. The epidermal growth factor receptor mutation, anaplastic lymphoma kinase and programmed death-ligand 1 investigation is necessary in the everyday clinical practice for the oncologic patient. Immunotherapy is nowadays the novel therapy for advanced stage non-small cell lung cancer with two agents nivolumab and pembrolizumab. In the current case series we will present adverse effects from our centers and comment on the treatment and follow-up of the patients.
Related Topics
Health Sciences
Medicine and Dentistry
Pulmonary and Respiratory Medicine
Authors
Paul Zarogoulidis, Panos Chinelis, Anastasia Athanasiadou, Theodora Tsiouda, Georgia Trakada, Anastasios Kallianos, Lemonia Veletza, Dimitris Hatzibougias, Electra Mihalopoulou, Eirini Goupou, Christoforos Kosmidis, Chrysanthi Sardeli, Haidong Huang,